APA (7th ed.) Citation

AJ, C., D, T., KS, A., WF, S., HS, R., ME, M., . . . LJ, E. (2020). MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(10), 1059. https://doi.org/10.1200/JCO.19.01027

Chicago Style (17th ed.) Citation

AJ, Chien, et al. "MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive And/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 38, no. 10 (2020): 1059. https://doi.org/10.1200/JCO.19.01027.

MLA (9th ed.) Citation

AJ, Chien, et al. "MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive And/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 38, no. 10, 2020, p. 1059, https://doi.org/10.1200/JCO.19.01027.